儿童克罗恩病患者联合使用免疫调节剂对阿达木单抗药代动力学、疗效和安全性的影响:一项事后分析
该事后分析基于IMAgINE 1研究,评估儿童中重度克罗恩病患者联合免疫调节剂与阿达木单抗单药治疗在疗效、药代动力学、免疫原性和安全性上的差异。结果显示两组在第4、26、52周的应答和缓解率均无显著差异,阿达木单抗血清谷浓度和严重感染率亦无显著差异。
要点
- 第4周联合组与单药组应答率分别为79%和87%,缓解率分别为26%和30%,均无显著差异。
- 第26周和第52周两组应答和缓解率均无显著差异。
- 两组阿达木单抗血清谷浓度和严重感染率(7% vs 6%)无显著差异。
核心结论
- 分析发现阿达木单抗单药治疗与免疫调节剂联合阿达木单抗治疗在应答或缓解方面无统计学显著差异。
- 两组严重不良事件和感染性不良事件发生率相似。
研究设计与样本
- IMAgINE 1研究的事后分析,纳入6-17岁中重度克罗恩病患者192例,基线及第2周接受按体重阿达木单抗诱导治疗,第4周188例随机分配至高剂量或低剂量阿达木单抗。
- 基线时接受免疫调节剂(研究者决定)的患者维持稳定剂量至第26周,之后可停用免疫调节剂;在第4、26、52周测量阿达木单抗血清浓度,每次访视评估安全性。
- 数据分析采用无应答者填补法(NRI;第4周)或改良NRI(第26周;第52周)。
主要发现
- 第4周,基线使用免疫调节剂组(n=117)与未使用组(n=71)的应答率分别为79%和87%(P=0.235),缓解率分别为26%和30%(P=0.737)。
- 第26周,基线使用与未使用免疫调节剂组的应答率分别为68%和55%(P=0.086),缓解率分别为41%和30%(P=0.122)。
- 第52周,使用免疫调节剂组(n=82)与未使用组(n=106)的应答率分别为56%和46%(P=0.189),缓解率分别为38%和33%(P=0.539)。
- 两组阿达木单抗血清谷浓度和严重感染率(7% vs 6%)无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the IMAgINE 1 study, adalimumab induced and maintained remission of moderate-to-severe Crohn's disease in children. AIM: To assess the efficacy, pharmacokinetics, immunogenicity and safety of immunomodulator and adalimumab combination therapy vs adalimumab monotherapy in paediatric patients with Crohn's disease. METHODS: Patients 6-17 years old with moderate-to-severe Crohn's disease (n = 192) received weight-based adalimumab induction at baseline and week 2. At week 4, 188 patients were randomised to high-dose or low-dose adalimumab. Patients receiving immunomodulators (investigator's decision) at baseline maintained a stable dose until week 26; patients could then discontinue immunomodulators. Adalimumab serum concentrations were measured at weeks 4, 26 and 52. Safety was evaluated at each study visit. Data were analysed using non-responder imputation (NRI; week 4) or modified NRI (weeks 26; 52). RESULTS: At week 4, patients with (n = 117) and without (n = 71) baseline immunomodulator use had similar response (79%; 87%; P = 0.235) and remission (26%; 30%; P = 0.737) rates. At week 26, patients with and without baseline immunomodulators had no significant difference in response (68%; 55%; P = 0.086) or remission (41%; 30%; P = 0.122). At week 52, patients with (n = 82) and without (n = 106) immunomodulator use had no significant difference in response (56%; 46%; P = 0.189) or remission (38%; 33%; P = 0.539). Adalimumab serum trough concentrations and serious infection rates (7%; 6%) were not significantly different between groups. CONCLUSIONS: Analyses found no statistically significant difference in response or remission between patients receiving adalimumab monotherapy vs immunomodulator and adalimumab combination therapy. Serious and infectious adverse event rates were similar between groups.
引用
- Hyams JS, Dubinsky M, Rosh J, et al. The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis. Aliment Pharmacol Ther. 2018. PMID: 30506693. doi:10.1111/apt.15054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。